Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Significant Clot Risk with Implantable Heart Device

December 2, 2013 By Cleveland Clinic

Researchers Identify Biomarker that May Foretell Clot Formation in Heart Pump

A multicenter study published online in the New England Journal of Medicine has found an increase in blood clot formation in the HeartMate II left ventricular assist device (LVAD) compared to trial data and prior experience. LVAD-based clot formation is associated with an increased risk of death.

Data from Cleveland Clinic, Duke University Medical Center, and Washington University Barnes-Jewish Hospital found that clot formation, or thrombosis, is developing more frequently in patients receiving the HeartMate II. Since March 2011, clot formation has occurred in 8.4 percent of implants compared to 2.2 percent prior to that date. Additionally, the researchers found that when clots develop, they are occurring much more rapidly than previously noted, with the median time from implant to thrombosis decreasing from 18.6 months to 2.7 months since March 2011.

The researchers – led by Randall C. Starling, MD, MPH, Vice Chairman of Cardiovascular Medicine and Section Head of Heart Failure and Cardiac Transplant Medicine at Cleveland Clinic – also discovered that elevated levels of lactate dehydrogenase (LDH) in the blood mirrored the incidence of thrombosis in patients. They found that LDH levels more than doubled in the six weeks leading up to the diagnosis of thrombosis, identifying an important biomarker caused by hemolysis, or the destruction of red blood cells. Using LDH as a biomarker, physicians could identify HeartMate II patients who are developing pump thrombosis. Early identification and treatment in these patients might reverse the clotting process.

Dr. Starling and his coauthors examined the outcomes of 895 HeartMate II implants in 837 patients at their three institutions from 2004 to mid-2013. They observed 72 confirmed pump thromboses in 66 patients during that time, with the increase in thromboses occurring around March 2011. Confirmed pump thrombosis was defined as a blood clot found in or on the pump during pump exchange, heart transplant, or autopsy.

Patients who developed clots in their pumps were treated with urgent heart transplant or pump exchange and had a mortality rate equivalent to patients who did not have a clot. Mortality among patients with clotted pumps who did not receive a transplant or pump replacement was 48 percent at 90 days after the diagnosis of pump thrombosis.

“LVADs are important devices in heart failure treatment that have greatly improved the quality of life and survival of thousands of patients – patients who have very few, if any, other treatment options,” said Dr. Starling. “We must continue to rely on LVADs to provide life-sustaining treatment for patients while they wait for a scarce donor heart, and to sustain life in patients not eligible for heart transplant. Physicians and patients should take this updated risk profile into consideration when determining the best treatment course for advanced heart failure.”

Starling and his coauthors call for further research to be undertaken to identify any predisposing patient and device factors contributing to the increased incidence of thrombosis, as well as to investigate preventative and therapeutic strategies for patient management.

The HeartMate II device, manufactured by Thoratec Corp., is a mechanical heart pump used in the treatment of advanced heart failure. The device assists the heart’s pumping function by circulating blood in a continuous flow through the vascular system. The device is used primarily in patients in the late stages of heart failure to keep them alive until an organ becomes available for transplant. HeartMate II is also approved in the United States for use as destination therapy, or a permanent solution, in patients who are ineligible for a heart transplant.

This study began when physicians at Cleveland Clinic observed an apparent increase in device thrombosis in patients who received the HeartMate II. A subsequent Cleveland Clinic internal quality review revealed an abrupt increase in HeartMate II device thrombosis. At this point, the initial Cleveland Clinic findings were immediately reported to Thoratec and the FDA. To confirm and strengthen the findings for scientific publication, data from two additional experienced LVAD centers were pooled and similar results were found.

Dr. Starling has consulted for Thoratec Corp. but instructed them to donate all compensation to not-for-profit causes or to the Cleveland Clinic to support research and education.

Related Articles Read More >

A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
An illustration of a neurosurgeon using a robotic endoscope to remove a brain tumor.
MDO Nitinol Innovation Special Report
A photo of Highridge Medical CEO Rebecca Whitney.
Highridge Medical is betting on this spine tech
A photo of the miniature Auxilium Biotechnologies implants made on the International Space Station.
Implants 3D-printed in space could enable nerve regeneration
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe